Abstract Visceral leishmaniasis is a devastating neglected parasitic disease caused by infection with Leishmania donovani. It life cycle has two stages with promastigote (insect stage) and amastigote (animal stage) morphologies. Miltefosine is currently the only commercially available oral drug available to treat leishmaniasis and recent evidence suggests clinical resistance has emerged. Due to the importance of this drug and the scarcity of new drugs in the pipeline, work has been done on understanding the mechanism(s) of miltefosine, yet the mechanism of action for resistance is still not known. In previous studies investigators generated miltefosine resistance on the insect vector stage (promastigotes), yet there is an important gap in u...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
Miltefosine (hexadecylphosphocholine, MIL), registered as Impavido<SUP>®</SUP>, has become the first...
Leishmania donovani promastigote lines resistant to hexadecylphosphocholine (HePC, miltefosine) at 2...
Abstract Visceral leishmaniasis is a devastating neglected parasitic disease caused by infection wit...
Miltefosine (hexadecylphosphocholine) is the first oral antileishmanial drug. In this study, we addr...
<div><p>Trypanosomatid parasites of the genus <i>Leishmania</i> are the causative agents of leishman...
Trypanosomatid parasites of the genus Leishmania are the causative agents of leishmaniasis, a neglec...
International audienceDuring the last decade miltefosine (MIL) has been used as first-line treatment...
<div><p>Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, an...
n this study, we followed the genomic, lipidomic and metabolomic changes associated with the selecti...
Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its ef...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
In this study we followed the genomic, lipidomic and metabolomic changes associated with the selecti...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
Miltefosine (hexadecylphosphocholine, MIL), registered as Impavido<SUP>®</SUP>, has become the first...
Leishmania donovani promastigote lines resistant to hexadecylphosphocholine (HePC, miltefosine) at 2...
Abstract Visceral leishmaniasis is a devastating neglected parasitic disease caused by infection wit...
Miltefosine (hexadecylphosphocholine) is the first oral antileishmanial drug. In this study, we addr...
<div><p>Trypanosomatid parasites of the genus <i>Leishmania</i> are the causative agents of leishman...
Trypanosomatid parasites of the genus Leishmania are the causative agents of leishmaniasis, a neglec...
International audienceDuring the last decade miltefosine (MIL) has been used as first-line treatment...
<div><p>Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, an...
n this study, we followed the genomic, lipidomic and metabolomic changes associated with the selecti...
Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its ef...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
In this study we followed the genomic, lipidomic and metabolomic changes associated with the selecti...
In this study, we followed the genomic, lipidomic and metabolomic changes associated with the select...
Miltefosine (hexadecylphosphocholine, MIL), registered as Impavido<SUP>®</SUP>, has become the first...
Leishmania donovani promastigote lines resistant to hexadecylphosphocholine (HePC, miltefosine) at 2...